ResMed Company Profile (NYSE:RMD)

About ResMed (NYSE:RMD)

ResMed logoResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:RMD
  • CUSIP: 76115210
  • Web: www.resmed.com
Capitalization:
  • Market Cap: $10.35 billion
  • Outstanding Shares: 142,209,000
Average Prices:
  • 50 Day Moving Avg: $75.98
  • 200 Day Moving Avg: $72.38
  • 52 Week Range: $56.59 - $79.63
P/E:
  • Trailing P/E Ratio: 30.33
  • Foreward P/E Ratio: 21.73
  • P/E Growth: 2.37
Sales & Book Value:
  • Annual Revenue: $2.07 billion
  • Price / Sales: 5.00
  • Book Value: $13.79 per share
  • Price / Book: 5.28
Dividend:
  • Annual Dividend: $1.40
  • Dividend Yield: 1.9%
Profitability:
  • EBIDTA: $568.89 million
  • Net Margins: 16.56%
  • Return on Equity: 21.99%
  • Return on Assets: 11.86%
Debt:
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 4.57%
  • Quick Ratio: 3.82%
Misc:
  • Average Volume: 1.25 million shs.
  • Beta: 0.83
  • Short Ratio: 13.12
 

Frequently Asked Questions for ResMed (NYSE:RMD)

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Wednesday, August 2nd. Investors of record on Thursday, August 17th will be given a dividend of $0.35 per share on Thursday, September 21st. This represents a $1.40 annualized dividend and a dividend yield of 1.92%. The ex-dividend date of this dividend is Tuesday, August 15th. This is a positive change from ResMed's previous quarterly dividend of $0.33. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) issued its earnings results on Tuesday, August, 1st. The company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.02. The business earned $556.69 million during the quarter, compared to analysts' expectations of $557.68 million. ResMed had a return on equity of 21.99% and a net margin of 16.56%. The business's revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the business posted $0.74 earnings per share. View ResMed's Earnings History.

When will ResMed make its next earnings announcement?

ResMed is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for ResMed.

Where is ResMed's stock going? Where will ResMed's stock price be in 2017?

11 analysts have issued 1-year price objectives for ResMed's shares. Their forecasts range from $50.00 to $72.00. On average, they anticipate ResMed's share price to reach $62.57 in the next year. View Analyst Ratings for ResMed.

What are analysts saying about ResMed stock?

Here are some recent quotes from research analysts about ResMed stock:

  • 1. According to Zacks Investment Research, "ResMed exited fourth-quarter fiscal 2017 on a promising note with earnings and revenues beating the Zacks Consensus Estimate. The company achieved high single-digit global revenue growth this quarter, led by sales of sleep devices, respiratory care devices, mask systems and software solutions. Also, Brightree has acted as a significant contributor to the company’s operating results through 2017. Notably, over the last three months, ResMed is trading significantly above the broader industry. We believe, ResMed’s product launches and strategies to gain traction in the SDB market are expected to boost its performance further in the near term. Its recent published favorable study result on COPD is expected to open up new scope in this line. Yet, challenges like competitive bidding and reimbursement issues continue to plague the stock. Rising operating expenses and a weak operating margin are other major woes for ResMed." (8/3/2017)
  • 2. Needham & Company LLC analysts commented, "RMD’s revenue missed consensus but its EPS beat consensus in F4Q17. Organic revenue growth increased to 8% in F4Q17 from 6% in F3Q17 as RMD saw higher flow generator growth partly offset by a slowdown in masks due to supply constraints in the first two months of the quarter. While RMD’s gross margin was slightly lower than expected, it was more than offset by lower than expected SG&A and R&D allowing RMD’s operating margin to beat our estimate. We maintain our Underperform rating since we believe that RMD’s longer-run revenue growth potential is similar to its large-cap peers (mid-single digit revenue growth and 8-10% EPS growth —possibly generous since we note that RMD’s EPS growth has averaged just 4% for the past three years) while its multiple is at a premium (CY17E P/E of 26.5x vs. large-cap med tech peers at 24.3x)." (8/2/2017)

Who are some of ResMed's key competitors?

Who are ResMed's key executives?

ResMed's management team includes the folowing people:

  • Rob Douglas, President, Chief Operating Officer
  • Michael Farrell, Chief Executive Officer, Director
  • Brett A. Sandercock, Chief Financial Officer
  • Jim Hollingshead Ph.D., President - Americas
  • Anne Reiser, President – Europe & Asia Pacific
  • David Pendarvis, Chief Administrative Officer, Global General Counsel, Company Secretary
  • Agnes Lee, Senior Director - Investor Relations
  • Peter C. Farrell Ph.D., Non-Executive Chairman of the Board
  • Ronald R. Taylor, Lead Independent Director
  • Carol J. Burt, Independent Director

Who owns ResMed stock?

ResMed's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.01%), Vanguard Group Inc. (8.38%), Capital World Investors (7.09%), FMR LLC (3.90%), Baillie Gifford & Co. (3.42%) and State Street Corp (3.24%). Company insiders that own ResMed stock include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Donald Darkin, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Sulpizio, Robert Andrew Douglas, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

Who sold ResMed stock? Who is selling ResMed stock?

ResMed's stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, TIAA CREF Investment Management LLC, Capital World Investors, Russell Investments Group Ltd., Schroder Investment Management Group, JPMorgan Chase & Co., Baillie Gifford & Co. and Bank of Montreal Can. Company insiders that have sold ResMed stock in the last year include Brett Sandercock, Christopher G Roberts, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell and Richard Sulpizio. View Insider Buying and Selling for ResMed.

Who bought ResMed stock? Who is buying ResMed stock?

ResMed's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Koch Industries Inc., BlackRock Inc., Vanguard Group Inc., First Trust Advisors LP, Janus Henderson Group PLC, Quantitative Investment Management LLC and Northern Trust Corp. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

How do I buy ResMed stock?

Shares of ResMed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of ResMed stock can currently be purchased for approximately $72.79.


MarketBeat Community Rating for ResMed (NYSE RMD)
Community Ranking:  1.5 out of 5 ( )
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  377 (Vote Underperform)
Total Votes:  545
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ResMed (NYSE:RMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Sell Ratings, 5 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 1.82)
Consensus Price Target: $62.57 (14.04% downside)

Analysts' Ratings History for ResMed (NYSE:RMD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017Credit Suisse GroupDowngradeOutperform -> NeutralLowView Rating Details
8/2/2017BMO Capital MarketsBoost Price TargetMarket Perform$61.00 -> $70.00MediumView Rating Details
8/2/2017Needham & Company LLCReiterated RatingSellHighView Rating Details
8/2/2017Citigroup Inc.UpgradeNeutral -> BuyHighView Rating Details
8/2/2017Bank of America CorporationDowngradeBuy -> NeutralHighView Rating Details
4/28/2017Jefferies Group LLCReiterated RatingSell$56.00LowView Rating Details
4/20/2017J P Morgan Chase & CoDowngradeOverweight -> Neutral$72.00 -> $71.00MediumView Rating Details
4/13/2017William BlairReiterated RatingOutperformLowView Rating Details
2/6/2017Canaccord GenuityReiterated RatingHold$59.00N/AView Rating Details
1/24/2017Barclays PLCBoost Price TargetUnderweight$55.00 -> $60.00N/AView Rating Details
8/29/2016Northland SecuritiesSet Price TargetSell$50.00N/AView Rating Details
4/27/2016MacquarieUpgradeUnderperform -> NeutralN/AView Rating Details
4/27/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$65.00 -> $57.00N/AView Rating Details
10/6/2015Deutsche Bank AGUpgradeSell -> Hold$53.00 -> $56.00N/AView Rating Details
9/24/2015Goldman Sachs Group, Inc. (The)UpgradeNeutral -> Conviction-BuyN/AView Rating Details
(Data available from 8/17/2015 forward)

Earnings

Earnings History for ResMed (NYSE:RMD)
Earnings by Quarter for ResMed (NYSE:RMD)
Earnings History by Quarter for ResMed (NYSE RMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/23/2017$0.66N/AView Earnings Details
8/1/2017Q4 2017$0.75$0.77$557.68 million$556.69 millionViewListenView Earnings Details
4/27/2017Q3 2017$0.70$0.71$525.84 million$514.20 millionViewN/AView Earnings Details
1/23/2017Q217$0.70$0.73$518.60 million$530.40 millionViewN/AView Earnings Details
10/25/2016Q117$0.64$0.62$475.05 million$465.45 millionViewListenView Earnings Details
7/28/2016Q416$0.74$0.74$512.37 million$518.60 millionViewListenView Earnings Details
4/26/2016Q316$0.69$0.68$455.32 million$453.90 millionViewListenView Earnings Details
1/21/2016Q216$0.66$0.69$445.46 million$454.54 millionViewListenView Earnings Details
10/22/2015Q116$0.59$0.58$406.26 million$411.70 millionViewListenView Earnings Details
7/30/2015Q415$0.65$0.68$436.27 million$453.10 millionViewListenView Earnings Details
4/23/2015Q315$0.65$0.65$425.76 million$422.50 millionViewListenView Earnings Details
1/22/2015Q215$0.62$0.64$408.20 million$423.00 millionViewListenView Earnings Details
10/23/2014Q115$0.58$0.58$375.00 million$380.40 millionViewListenView Earnings Details
7/31/2014Q414$0.66$0.64$433.42 million$415.20 millionViewListenView Earnings Details
4/23/2014Q314$0.64$0.63$401.00 million$397.80 millionViewListenView Earnings Details
1/23/2014Q214$0.63$0.60$398.09 million$384.30 millionViewListenView Earnings Details
10/24/2013Q114$0.58$0.56$372.28 million$357.66 millionViewListenView Earnings Details
8/1/2013Q4 2013$0.62$0.62$410.89 million$414.60 millionViewListenView Earnings Details
4/25/2013Q3 2013$0.58$0.58$386.76 million$383.60 millionViewListenView Earnings Details
1/24/2013Q2 2013$0.51$0.53$363.76 million$376.50 millionViewListenView Earnings Details
10/25/2012$0.46$0.49ViewN/AView Earnings Details
8/2/2012$0.49$0.53ViewN/AView Earnings Details
4/26/2012$0.41$0.44ViewN/AView Earnings Details
1/26/2012$0.38$0.42ViewN/AView Earnings Details
10/24/2011$0.35$0.33ViewN/AView Earnings Details
8/4/2011$0.37$0.37ViewN/AView Earnings Details
4/28/2011$0.35$0.35ViewN/AView Earnings Details
1/27/2011$0.36$0.37ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ResMed (NYSE:RMD)
2017 EPS Consensus Estimate: $2.71
2018 EPS Consensus Estimate: $2.94
2019 EPS Consensus Estimate: $2.55
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.57$0.64$0.61
Q2 20173$0.69$0.70$0.69
Q3 20173$0.65$0.70$0.68
Q4 20173$0.70$0.76$0.73
Q1 20182$0.63$0.65$0.64
Q2 20182$0.74$0.78$0.76
Q3 20182$0.72$0.75$0.74
Q4 20182$0.77$0.84$0.81
Q1 20191$0.71$0.71$0.71
Q2 20191$0.84$0.84$0.84
Q3 20191$0.81$0.81$0.81
Q4 20191$0.19$0.19$0.19
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for ResMed (NYSE:RMD)
Next Dividend:9/21/2017
Annual Dividend:$1.40
Dividend Yield:1.92%
Dividend Growth:14.50% (3 Year Average)
Payout Ratio:58.09% (Trailing 12 Months of Earnings)
46.20% (Based on This Year's Estimates)
41.79% (Based on Next Year's Estimates)
Dividend Payments by Quarter for ResMed (NYSE:RMD)

Dividend History by Quarter for ResMed (NYSE RMD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/2/2017quarterly$0.351.93%8/15/20178/17/20179/21/2017
4/27/2017quarterly$0.331.94%5/9/20175/11/20176/15/2017
1/23/2017quarterly$0.331.89%2/7/20172/9/20173/16/2017
10/25/2016quarterly$0.332.18%11/8/201611/10/201612/15/2016
7/28/2016quarterly$0.331.92%8/16/20168/18/20169/22/2016
4/26/2016quarterly$0.302.12%5/17/20165/19/20166/16/2016
1/21/2016quarterly$0.302.08%2/9/20162/11/20163/17/2016
10/22/2015quarterly$0.302.13%11/17/201511/19/201512/17/2015
7/30/2015quarterly$0.302.07%8/18/20158/20/20159/17/2015
4/24/2015quarterly$0.281.7%5/19/20155/21/20156/18/2015
1/23/2015quarterly$0.281.72%2/10/20152/12/20153/19/2015
10/27/2014quarterly$0.282.17%11/18/201411/20/201412/18/2014
8/1/2014quarterly$0.282.25%8/19/20148/21/20149/18/2014
4/24/2014quarterly$0.252.11%5/16/20145/20/20146/17/2014
1/24/2014quarterly$0.252.28%2/14/20142/19/20143/19/2014
10/25/2013quarterly$0.252.02%11/15/201311/19/201312/18/2013
8/2/2013quarterly$0.252.09%8/16/20138/20/20139/17/2013
4/29/2013quarterly$0.171.44%5/17/20135/21/20136/18/2013
1/25/2013quarterly$0.171.41%2/14/20132/19/20133/19/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for ResMed (NYSE:RMD)
Insider Ownership Percentage: 1.97%
Institutional Ownership Percentage: 60.66%
Insider Trades by Quarter for ResMed (NYSE:RMD)
Institutional Ownership by Quarter for ResMed (NYSE:RMD)
Insider Trades by Quarter for ResMed (NYSE:RMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2017Richard SulpizioDirectorSell24,390$73.85$1,801,201.50View SEC Filing  
8/4/2017Peter C FarrellDirectorSell20,000$75.15$1,503,000.00View SEC Filing  
8/3/2017David PendarvisInsiderSell6,364$72.10$458,844.40View SEC Filing  
8/1/2017Brett SandercockCFOSell1,250$77.49$96,862.50View SEC Filing  
7/14/2017James HollingsheadInsiderSell7,140$77.43$552,850.20View SEC Filing  
7/5/2017Peter C FarrellDirectorSell20,000$76.50$1,530,000.00View SEC Filing  
7/3/2017Brett SandercockCFOSell1,250$77.44$96,800.00View SEC Filing  
7/3/2017David PendarvisInsiderSell6,364$77.36$492,319.04View SEC Filing  
6/29/2017Jr. Gregor K EmmertInsiderBuy282,000$0.07$19,740.00
6/28/2017Jr. Gregor K EmmertInsiderBuy424,000$0.06$25,440.00
6/22/2017Richard SulpizioDirectorSell65,887$77.82$5,127,326.34View SEC Filing  
6/15/2017Gary W PaceDirectorSell24,390$76.00$1,853,640.00View SEC Filing  
6/5/2017David PendarvisInsiderSell6,365$72.62$462,226.30View SEC Filing  
6/5/2017Peter C FarrellDirectorSell20,000$72.65$1,453,000.00View SEC Filing  
6/1/2017Brett SandercockCFOSell1,250$71.02$88,775.00View SEC Filing  
5/4/2017Peter C FarrellDirectorSell20,000$68.75$1,375,000.00View SEC Filing  
5/3/2017David PendarvisInsiderSell6,365$69.55$442,685.75View SEC Filing  
5/1/2017Brett SandercockCFOSell1,250$68.60$85,750.00View SEC Filing  
4/17/2017James HollingsheadInsiderSell7,139$68.37$488,093.43View SEC Filing  
4/4/2017Peter C FarrellDirectorSell20,000$70.67$1,413,400.00View SEC Filing  
4/3/2017Brett SandercockCFOSell1,250$71.65$89,562.50View SEC Filing  
4/3/2017David PendarvisInsiderSell6,365$71.59$455,670.35View SEC Filing  
3/1/2017Brett SandercockCFOSell1,250$72.48$90,600.00View SEC Filing  
2/24/2017John P WarehamDirectorSell28,403$71.77$2,038,483.31View SEC Filing  
2/20/2017Christopher G RobertsDirectorSell10,000$71.91$719,100.00View SEC Filing  
2/15/2017Franz KozichDirectorBuy50,000$0.05$2,500.00
2/14/2017Warren Russell HawkinsDirectorBuy60,000$0.05$3,000.00
2/6/2017Peter C FarrellDirectorSell20,000$68.32$1,366,400.00View SEC Filing  
2/3/2017David PendarvisInsiderSell6,365$67.16$427,473.40View SEC Filing  
1/17/2017James HollingsheadInsiderSell7,084$64.44$456,492.96View SEC Filing  
1/4/2017Peter C FarrellDirectorSell20,000$62.14$1,242,800.00View SEC Filing  
1/3/2017David PendarvisInsiderSell6,365$61.95$394,311.75View SEC Filing  
12/5/2016David PendarvisInsiderSell6,365$60.00$381,900.00View SEC Filing  
12/5/2016Peter C FarrellDirectorSell20,000$59.83$1,196,600.00View SEC Filing  
11/4/2016Peter C FarrellDirectorSell20,000$57.28$1,145,600.00View SEC Filing  
11/3/2016David PendarvisInsiderSell6,033$57.79$348,647.07View SEC Filing  
10/18/2016James HollingsheadInsiderSell1,967$64.71$127,284.57View SEC Filing  
10/17/2016James HollingsheadInsiderSell5,264$64.43$339,159.52View SEC Filing  
10/17/2016Michael J FarrellCEOSell5,975$64.25$383,893.75View SEC Filing  
10/4/2016Peter C FarrellDirectorSell20,000$64.70$1,294,000.00View SEC Filing  
10/3/2016David PendarvisInsiderSell6,000$63.95$383,700.00View SEC Filing  
9/15/2016Michael J. FarrellCEOSell5,975$64.84$387,419.00View SEC Filing  
9/6/2016David PendarvisInsiderSell6,000$67.18$403,080.00View SEC Filing  
9/6/2016Peter C FarrellDirectorSell20,000$67.29$1,345,800.00View SEC Filing  
8/19/2016Gary W PaceDirectorSell36,000$69.93$2,517,480.00View SEC Filing  
8/17/2016Ronald R TaylorDirectorBuy2,487$69.13$171,926.31View SEC Filing  
8/16/2016Ronald R TaylorDirectorSell23,102$69.25$1,599,813.50View SEC Filing  
8/15/2016Michael J. FarrellCEOSell5,975$70.41$420,699.75View SEC Filing  
8/11/2016Brett SandercockCFOSell35,000$70.50$2,467,500.00View SEC Filing  
8/10/2016Richard SulpizioDirectorSell36,000$70.15$2,525,400.00View SEC Filing  
8/8/2016John P WarehamDirectorSell24,390$70.32$1,715,104.80View SEC Filing  
8/4/2016Peter C FarrellDirectorSell20,000$69.16$1,383,200.00View SEC Filing  
8/3/2016David PendarvisInsiderSell6,000$68.86$413,160.00View SEC Filing  
7/15/2016Michael J FarrellCEOSell5,975$65.03$388,554.25View SEC Filing  
7/14/2016James HollingsheadInsiderSell2,753$65.02$179,000.06View SEC Filing  
7/7/2016Peter C FarrellDirectorSell20,000$63.62$1,272,400.00View SEC Filing  
7/5/2016David PendarvisInsiderSell6,000$63.62$381,720.00View SEC Filing  
6/15/2016James HollingsheadInsiderSell4,458$59.40$264,805.20View SEC Filing  
6/15/2016Michael J FarrellCEOSell5,975$59.63$356,289.25View SEC Filing  
6/6/2016Peter C FarrellDirectorSell20,000$59.82$1,196,400.00View SEC Filing  
6/3/2016David PendarvisInsiderSell6,000$59.41$356,460.00View SEC Filing  
5/16/2016Michael J FarrellCEOSell5,975$57.64$344,399.00View SEC Filing  
5/4/2016Peter C FarrellDirectorSell20,000$55.90$1,118,000.00View SEC Filing  
5/3/2016David PendarvisInsiderSell6,000$56.02$336,120.00View SEC Filing  
4/15/2016Michael J FarrellCEOSell5,975$59.34$354,556.50View SEC Filing  
4/4/2016David PendarvisInsiderSell6,000$58.70$352,200.00View SEC Filing  
4/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00View SEC Filing  
3/15/2016James HollingsheadInsiderSell4,500$58.57$263,565.00View SEC Filing  
3/15/2016Michael J FarrellCEOSell5,975$58.57$349,955.75View SEC Filing  
3/11/2016Gary W PaceDirectorSell36,000$60.00$2,160,000.00View SEC Filing  
3/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00View SEC Filing  
3/3/2016David PendarvisInsiderSell6,000$57.26$343,560.00View SEC Filing  
2/29/2016Anne ReiserInsiderSell1,946$57.06$111,038.76View SEC Filing  
2/26/2016Brett SandercockCFOSell30,000$57.61$1,728,300.00View SEC Filing  
2/26/2016Richard SulpizioDirectorSell36,000$57.88$2,083,680.00View SEC Filing  
2/25/2016Peter C FarrellDirectorSell139,980$57.31$8,022,253.80View SEC Filing  
2/16/2016Michael J. FarrellCEOSell5,975$58.20$347,745.00View SEC Filing  
2/4/2016Peter C. FarrellDirectorSell20,000$57.70$1,154,000.00View SEC Filing  
2/3/2016David PendarvisinsiderSell6,000$57.43$344,580.00View SEC Filing  
1/27/2016Franz KozichDirectorBuy60,000$0.04$2,100.00
1/15/2016Michael J. FarrellCEOSell5,975$53.07$317,093.25View SEC Filing  
1/4/2016David PendarvisinsiderSell6,000$52.16$312,960.00View SEC Filing  
1/4/2016Peter C. FarrellDirectorSell20,000$52.22$1,044,400.00View SEC Filing  
1/4/2016Robert Andrew DouglasCOOSell6,337$52.97$335,670.89View SEC Filing  
12/15/2015James HollingsheadInsiderSell4,500$55.95$251,775.00View SEC Filing  
12/3/2015David PendarvisinsiderSell6,000$59.38$356,280.00View SEC Filing  
12/1/2015Robert Andrew DouglasCOOSell6,333$59.77$378,523.41View SEC Filing  
11/25/2015Warren Russell HawkinsDirectorBuy15,000$0.06$825.00
11/24/2015Warren Russell HawkinsDirectorBuy3,000$0.06$165.00
11/20/2015Christopher G RobertsDirectorSell12,000$59.03$708,360.00View SEC Filing  
11/16/2015Michael J. FarrellCEOSell5,975$57.03$340,754.25View SEC Filing  
11/12/2015Donald DarkininsiderSell25,442$57.72$1,468,512.24View SEC Filing  
11/2/2015Robert Andrew DouglasCOOSell6,333$57.60$364,780.80View SEC Filing  
10/27/2015Anne ReiserinsiderSell3,000$57.01$171,030.00View SEC Filing  
10/15/2015Michael J. FarrellCEOSell5,975$55.35$330,716.25View SEC Filing  
10/5/2015David PendarvisinsiderSell5,500$52.47$288,585.00View SEC Filing  
10/5/2015Robert Andrew DouglasCOOSell6,333$52.13$330,139.29View SEC Filing  
10/1/2015Peter C. FarrellChairmanSell27,169$50.93$1,383,717.17View SEC Filing  
9/15/2015James HollingsheadInsiderSell4,455$50.67$225,734.85View SEC Filing  
9/15/2015Michael J. FarrellCEOSell5,975$50.89$304,067.75View SEC Filing  
9/3/2015David PendarvisinsiderSell5,500$51.78$284,790.00View SEC Filing  
9/3/2015Robert Andrew DouglasCOOSell6,333$52.04$329,569.32View SEC Filing  
9/1/2015Peter C. FarrellChairmanSell36,000$50.82$1,829,520.00View SEC Filing  
8/28/2015Anne ReiserinsiderSell6,000$52.26$313,560.00View SEC Filing  
8/27/2015Richard SulpizioDirectorSell10,860$51.83$562,873.80View SEC Filing  
8/17/2015Michael J FarrellCEOSell5,975$55.54$331,851.50View SEC Filing  
7/15/2015Michael J FarrellCEOSell5,975$57.59$344,100.25View SEC Filing  
7/6/2015David PendarvisInsiderSell5,500$55.19$303,545.00View SEC Filing  
7/1/2015Peter C FarrellChairmanSell36,000$55.61$2,001,960.00View SEC Filing  
7/1/2015Robert Andrew DouglasCOOSell6,333$56.59$358,384.47View SEC Filing  
6/15/2015Michael J FarrellCEOSell5,975$57.87$345,773.25View SEC Filing  
6/3/2015David PendarvisInsiderSell5,500$59.41$326,755.00View SEC Filing  
6/1/2015Peter C FarrellChairmanSell36,000$59.25$2,133,000.00View SEC Filing  
6/1/2015Robert Andrew DouglasCOOSell6,333$59.22$375,040.26View SEC Filing  
5/4/2015David PendarvisInsiderSell5,500$65.10$358,050.00View SEC Filing  
4/6/2015David PendarvisInsiderSell5,500$72.60$399,300.00View SEC Filing  
4/1/2015Peter C FarrellChairmanSell36,000$70.70$2,545,200.00View SEC Filing  
4/1/2015Robert Andrew DouglasCOOSell6,333$70.67$447,553.11View SEC Filing  
3/27/2015Warren Russell HawkinsDirectorBuy10,000$0.09$900.00
3/26/2015Warren Russell HawkinsDirectorBuy10,000$0.08$800.00
3/16/2015Anne ReiserInsiderSell4,000$69.10$276,400.00View SEC Filing  
3/16/2015Michael J FarrellCEOSell5,975$69.10$412,872.50View SEC Filing  
3/9/2015Anne ReiserInsiderSell3,000$66.75$200,250.00View SEC Filing  
3/2/2015Peter C FarrellChairmanSell36,000$64.64$2,327,040.00View SEC Filing  
3/2/2015Robert Andrew DouglasCOOSell6,333$64.39$407,781.87View SEC Filing  
2/17/2015Anne ReiserInsiderSell5,000$66.11$330,550.00View SEC Filing  
2/5/2015David PendarvisInsiderSell5,500$62.35$342,925.00View SEC Filing  
2/4/2015John P WarehamDirectorSell36,000$63.49$2,285,640.00View SEC Filing  
2/3/2015Brett SandercockCFOSell18,670$62.82$1,172,849.40View SEC Filing  
2/3/2015Robert Andrew DouglasCOOSell6,333$62.35$394,862.55View SEC Filing  
2/2/2015Peter C FarrellChairmanSell36,000$61.97$2,230,920.00View SEC Filing  
1/26/2015Gary W PaceDirectorSell48,000$66.77$3,204,960.00View SEC Filing  
1/5/2015David PendarvisInsiderSell5,500$57.09$313,995.00View SEC Filing  
1/2/2015Peter C FarrellChairmanSell36,000$56.99$2,051,640.00View SEC Filing  
1/2/2015Robert Andrew DouglasCOOSell8,000$56.99$455,920.00View SEC Filing  
12/1/2014Peter C FarrellChairmanSell36,000$53.28$1,918,080.00View SEC Filing  
12/1/2014Robert Andrew DouglasCOOSell8,000$52.93$423,440.00View SEC Filing  
11/18/2014Peter C FarrellChairmanSell36,000$52.39$1,886,040.00View SEC Filing  
11/3/2014David PendarvisInsiderSell3,557$52.00$184,964.00View SEC Filing  
11/3/2014Robert Andrew DouglasCOOSell8,000$51.84$414,720.00View SEC Filing  
10/29/2014Peter C FarrellChairmanSell119,204$51.84$6,179,535.36View SEC Filing  
10/3/2014David PendarvisInsiderSell5,000$49.84$249,200.00View SEC Filing  
10/1/2014Robert Andrew DouglasCOOSell8,000$49.11$392,880.00View SEC Filing  
9/15/2014Michael J FarrellCEOSell3,200$52.41$167,712.00View SEC Filing  
9/5/2014Brett SandercockCFOSell10,000$52.99$529,900.00View SEC Filing  
9/3/2014Brett SandercockCFOSell10,000$53.23$532,300.00View SEC Filing  
9/3/2014David PendarvisInsiderSell5,000$53.23$266,150.00View SEC Filing  
8/22/2014Anne ReiserInsiderSell3,000$53.37$160,110.00View SEC Filing  
8/4/2014David PendarvisInsiderSell5,000$49.12$245,600.00View SEC Filing  
8/1/2014Peter C FarrellDirectorSell25,000$49.04$1,226,000.00View SEC Filing  
8/1/2014Robert Andrew DouglasCOOSell8,000$48.95$391,600.00View SEC Filing  
7/15/2014Michael J FarrellCEOSell3,200$49.22$157,504.00View SEC Filing  
7/3/2014David PendarvisInsiderSell5,000$50.04$250,200.00View SEC Filing  
7/1/2014Peter C FarrellDirectorSell25,000$50.09$1,252,250.00View SEC Filing  
7/1/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
6/16/2014Michael J FarrellCEOSell3,200$53.20$170,240.00View SEC Filing  
6/3/2014David PendarvisInsiderSell5,000$49.76$248,800.00View SEC Filing  
6/2/2014Peter C FarrellDirectorSell25,000$49.57$1,239,250.00View SEC Filing  
6/2/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
5/29/2014Christopher G RobertsDirectorSell25,000$49.73$1,243,250.00View SEC Filing  
5/15/2014Michael FarrellCEOSell3,700$50.54$186,998.00View SEC Filing  
5/13/2014John WarehamDirectorSell18,000$51.00$918,000.00View SEC Filing  
5/8/2014Brett SandercockCFOSell5,000$50.00$250,000.00View SEC Filing  
5/6/2014Brett SandercockCFOSell4,290$50.00$214,500.00View SEC Filing  
5/1/2014Peter FarrellDirectorSell25,000$49.80$1,245,000.00View SEC Filing  
5/1/2014Robert Andrew DouglasCOOSell8,000$49.75$398,000.00View SEC Filing  
4/29/2014David PendarvisInsiderSell15,000$50.01$750,150.00View SEC Filing  
4/21/2014Peter FarrellDirectorSell75,000$48.01$3,600,750.00View SEC Filing  
4/4/2014David PendarvisInsiderSell5,000$44.95$224,750.00View SEC Filing  
2/12/2014Brett SandercockCFOSell10,687$46.00$491,602.00View SEC Filing  
1/9/2014Peter FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
12/2/2013Robert Andrew DouglasCOOSell8,000$49.10$392,800.00View SEC Filing  
11/20/2013Brett SandercockCFOSell15,000$51.06$765,900.00View SEC Filing  
11/20/2013James HollingsheadInsiderSell4,000$51.24$204,960.00View SEC Filing  
11/12/2013Donald DarkinInsiderSell31,063$50.04$1,554,392.52View SEC Filing  
10/29/2013David PendarvisInsiderSell37,744$50.42$1,903,052.48View SEC Filing  
10/1/2013Peter C FarrellDirectorSell25,000$53.21$1,330,250.00View SEC Filing  
10/1/2013Robert Andrew DouglasCOOSell8,000$53.20$425,600.00View SEC Filing  
9/9/2013Gary W PaceDirectorSell12,000$50.05$600,600.00View SEC Filing  
9/5/2013Peter C FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
9/3/2013Robert Andrew DouglasCOOSell8,000$47.51$380,080.00View SEC Filing  
8/28/2013Michael QuinnDirectorSell48,000$48.34$2,320,320.00View SEC Filing  
8/27/2013Brett SandercockCFOSell5,000$49.00$245,000.00View SEC Filing  
8/26/2013Christopher RobertsDirectorSell10,000$49.49$494,900.00View SEC Filing  
8/1/2013Robert Andrew DouglasCOOSell8,000$48.57$388,560.00View SEC Filing  
6/3/2013Robert Andrew DouglasCOOSell8,000$47.96$383,680.00View SEC Filing  
5/24/2013Christopher G RobertsDirectorSell20,000$49.45$989,000.00View SEC Filing  
5/22/2013John P WarehamDirectorSell18,000$50.20$903,600.00View SEC Filing  
5/13/2013Michael A QuinnDirectorSell15,000$50.94$764,100.00View SEC Filing  
5/8/2013Brett SandercockCFOSell28,000$48.97$1,371,160.00View SEC Filing  
2/4/2013Robert Andrew DouglasCOOSell8,000$44.14$353,120.00View SEC Filing  
8/8/2012Michael J FarrellInsiderSell30,000$35.58$1,067,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ResMed (NYSE:RMD)
Latest Headlines for ResMed (NYSE:RMD)
Source:
DateHeadline
finance.yahoo.com logoEarnings Review and Free Research Report: ResMed Adjusted Diluted EPS Increased 4%
finance.yahoo.com - August 16 at 7:19 AM
nasdaq.com logoResMed Inc. (RMD) Ex-Dividend Date Scheduled for August 15, 2017 - Nasdaq
www.nasdaq.com - August 15 at 6:47 AM
nasdaq.com logoResMed Inc. (RMD) Ex-Dividend Date Scheduled for August 15, 2017 - Nasdaq
www.nasdaq.com - August 15 at 6:47 AM
americanbankingnews.com logoRichard Sulpizio Sells 24,390 Shares of ResMed Inc. (RMD) Stock
www.americanbankingnews.com - August 11 at 4:20 PM
finance.yahoo.com logoCorporate News Blog - Bionix(R) Radiation Therapy Signs on Varian Medical Systems as Distributor for its Brachytherapy Applicators
finance.yahoo.com - August 11 at 8:07 AM
americanbankingnews.com logoResMed Inc. (NYSE:RMD) Lowered to "Neutral" at Credit Suisse Group
www.americanbankingnews.com - August 8 at 7:34 PM
finance.yahoo.com logoResMed, Inc. :RMD-US: Earnings Analysis: 2017 By the Numbers : August 7, 2017
finance.yahoo.com - August 8 at 6:42 AM
americanbankingnews.com logoResMed Inc. (NYSE:RMD) Director Peter C. Farrell Sells 20,000 Shares
www.americanbankingnews.com - August 7 at 7:22 PM
nasdaq.com logoResMed Inc (RMD) Files 10-K for the Fiscal Year Ended on June 30 ... - Nasdaq
www.nasdaq.com - August 6 at 4:46 AM
seekingalpha.com logoResMed: Buy On The Dip
seekingalpha.com - August 5 at 6:42 AM
americanbankingnews.com logoResMed Inc. (NYSE:RMD) Insider David Pendarvis Sells 6,364 Shares
www.americanbankingnews.com - August 4 at 8:22 PM
americanbankingnews.com logoQ4 2018 EPS Estimates for ResMed Inc. (NYSE:RMD) Boosted by Analyst
www.americanbankingnews.com - August 4 at 7:10 PM
finance.yahoo.com logoResMed, Inc. breached its 50 day moving average in a Bearish Manner : RMD-US : August 3, 2017
finance.yahoo.com - August 4 at 7:43 AM
americanbankingnews.com logoQ3 2018 Earnings Estimate for ResMed Inc. (RMD) Issued By William Blair
www.americanbankingnews.com - August 3 at 2:44 PM
americanbankingnews.com logoQ1 2018 EPS Estimates for ResMed Inc. Lowered by Jefferies Group (NYSE:RMD)
www.americanbankingnews.com - August 3 at 1:58 PM
americanbankingnews.com logoZacks Investment Research Lowers ResMed Inc. (NYSE:RMD) to Hold
www.americanbankingnews.com - August 3 at 12:30 PM
americanbankingnews.com logoResMed Inc. (NYSE:RMD) Announces Quarterly Dividend of $0.35
www.americanbankingnews.com - August 2 at 4:53 PM
nasdaq.com logoRelative Strength Alert For ResMed - Nasdaq.com - Nasdaq
www.nasdaq.com - August 2 at 3:57 PM
nasdaq.com logoResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track - Nasdaq
www.nasdaq.com - August 2 at 3:57 PM
americanbankingnews.com logoBrett Sandercock Sells 1,250 Shares of ResMed Inc. (RMD) Stock
www.americanbankingnews.com - August 2 at 10:28 AM
fool.com logoWhy the ResMed Inc. share price is falling today
www.fool.com.au - August 2 at 7:16 AM
seekingalpha.com logoResMed (RMD) Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - August 2 at 7:16 AM
finance.yahoo.com logoResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2017
finance.yahoo.com - August 2 at 7:16 AM
finance.yahoo.com logoResMed beats 4Q profit forecasts
finance.yahoo.com - August 2 at 7:16 AM
finance.yahoo.com logoEdited Transcript of RMD earnings conference call or presentation 1-Aug-17 8:30pm GMT
finance.yahoo.com - August 2 at 7:16 AM
americanbankingnews.com logoResMed Inc. (RMD) Issues Earnings Results
www.americanbankingnews.com - August 1 at 10:04 PM
americanbankingnews.com logoResMed Inc. (NYSE:RMD) Expected to Announce Quarterly Sales of $548.75 Million
www.americanbankingnews.com - July 31 at 7:12 AM
americanbankingnews.com logo Analysts Expect ResMed Inc. (RMD) Will Announce Earnings of $0.75 Per Share
www.americanbankingnews.com - July 30 at 12:18 AM
americanbankingnews.com logoResMed Inc. (NYSE:RMD) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - July 27 at 3:31 PM
americanbankingnews.com logoResMed Inc. (NYSE:RMD) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 24 at 6:52 PM
nasdaq.com logoIs a Surprise in Store for ResMed (RMD) in Q4 Earnings? - Nasdaq
www.nasdaq.com - July 22 at 8:17 AM
finance.yahoo.com logoIs a Surprise in Store for ResMed (RMD) in Q4 Earnings?
finance.yahoo.com - July 22 at 8:17 AM
americanbankingnews.com logoJames Hollingshead Sells 7,140 Shares of ResMed Inc. (RMD) Stock
www.americanbankingnews.com - July 17 at 4:26 PM
nasdaq.com logoResMed Sees Potential in SDB Market, Eyes Global Growth - Nasdaq
www.nasdaq.com - July 9 at 12:08 AM
americanbankingnews.com logo$548.75 Million in Sales Expected for ResMed Inc. (RMD) This Quarter
www.americanbankingnews.com - July 7 at 11:34 AM
americanbankingnews.com logoResMed Inc. (RMD) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - July 6 at 11:32 AM
americanbankingnews.com logoZacks: Analysts Expect ResMed Inc. (RMD) to Announce $0.75 EPS
www.americanbankingnews.com - July 5 at 8:28 PM
americanbankingnews.com logoInsider Selling: ResMed Inc. (NYSE:RMD) CFO Sells 1,250 Shares of Stock
www.americanbankingnews.com - July 5 at 7:45 PM
americanbankingnews.com logoResMed Inc. (RMD) Insider David Pendarvis Sells 6,364 Shares
www.americanbankingnews.com - July 5 at 7:28 PM
finance.yahoo.com logoResMed to Announce Fourth Quarter Fiscal Year 2017 Results
finance.yahoo.com - June 30 at 6:16 AM
americanbankingnews.com logoResMed Inc. (RMD) Insider Buys $19,740.00 in Stock
www.americanbankingnews.com - June 29 at 8:36 PM
americanbankingnews.com logoResMed Inc. (RMD) Insider Purchases $25,440.00 in Stock
www.americanbankingnews.com - June 29 at 4:28 PM
americanbankingnews.com logoResMed Inc. (RMD) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - June 28 at 1:50 PM
americanbankingnews.com logoResMed Inc. (RMD) Director Richard Sulpizio Sells 65,887 Shares
www.americanbankingnews.com - June 27 at 10:32 PM
americanbankingnews.com logoResMed Inc. (RMD) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 27 at 6:40 PM
nasdaq.com logoIJH, RMD, DRE, MSCI: ETF Outflow Alert - Nasdaq
www.nasdaq.com - June 27 at 7:49 AM
zacks.com logoResMed (RMD) at 52-Week High: What's Driving the Stock?
www.zacks.com - June 21 at 4:26 AM
americanbankingnews.com logoResMed Inc. (RMD) Upgraded to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - June 17 at 4:12 PM
americanbankingnews.com logoResMed Inc. (RMD) Director Gary W. Pace Sells 24,390 Shares
www.americanbankingnews.com - June 16 at 1:24 PM
seekingalpha.com logoResMed (RMD) Presents At The William Blair 2017 Growth Stock Conference - Slideshow
seekingalpha.com - June 15 at 12:10 AM

Social

Chart

ResMed (RMD) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by MarketBeat.com Staff